14 World Health Organization. WHO Consolidated Guidelines on Tuberculosis: Module 2: Screening: Systematic Screening for Tuberculosis Disease. Geneva, World Health Organization, 2021. 15 Nathavitharana RR, Garcia-Basteiro AL, Ruhwald M, et al. Reimagining the status quo: how close are we to rapid sputum-free tuberculosis diagnostics for all? EBioMedicine 2022 78: 103939. 16 Broger T, Koeppel L, Huerga H, et al. Diagnostic yield of urine lipoarabinomannan and sputum tuberculosis tests in people living with HIV: a systematic review and meta-analysis of individual participant data. Lancet Glob Heal 2023 11: e903–e916. 17 World Health Organization. Global Tuberculosis Report 2021. Geneva, World Health Organization, 2021. 18 Peter JG, Zijenah LS, Chanda D, et al. Effect on mortality of point-of-care, urine-based lipoarabinomannan testing to guide tuberculosis treatment initiation in HIV-positive hospital inpatients: a pragmatic, parallel-group, multicountry, open-label, randomised controlled trial. Lancet 2016 387: 1187–1197. 19 World Health Organization. Consensus Meeting Report: Development of a Target Product Profile (TPP) and a Framework for Evaluation for a Test for Predicting Progression from Tuberculosis Infection to Active Disease. Geneva, World Health Organization, 2017. 20 Jindani A, Harrison TS, Nunn AJ, et al. High-dose rifapentine with moxifloxacin for pulmonary tuberculosis. N Engl J Med 2014 371: 1599–1608. 21 Merle CS, Fielding K, Sow OB, et al. A four-month gatifloxacin-containing regimen for treating tuberculosis. N Engl J Med 2014 371: 1588–1598. 22 Gillespie SH, Crook AM, McHugh TD, et al. Four-month moxifloxacin-based regimens for drug-sensitive tuberculosis. N Engl J Med 2014 371: 1577–1587. 23 Dorman SE, Nahid P, Kurbatova EV, et al. Four-month rifapentine regimens with or without moxifloxacin for tuberculosis. N Engl J Med 2021 384: 1705–1718. 24 Nyang’wa B-T, Berry C, Kazounis E, et al. A 24-week, all-oral regimen for rifampin-resistant tuberculosis. N Engl J Med 2022 387: 2331–2343. 25 Conradie F, Bagdasaryan TR, Borisov S, et al. Bedaquiline-pretomanid-linezolid regimens for drug-resistant tuberculosis. N Engl J Med 2022 387: 810–823. 26 World Health Organization. WHO Consolidated Guidelines on Tuberculosis: Module 4: Treatment: Drug-resistant tuberculosis treatment. 2022 Update. Geneva, World Health Organization, 2022. 27 Ryckman TS, Dowdy DW, Kendall EA. Infectious and clinical tuberculosis trajectories: Bayesian modeling with case finding implications. Proc Natl Acad Sci USA 2022 119: e2211045119. 28 Emery JC, Dodd PJ, Banu S, et al. Estimating the contribution of subclinical tuberculosis disease to transmission – an individual patient data analysis from prevalence surveys. medRxiv 2022 pre-print [DOI: https://doi.org/10.1101/2022.06.09.22276188]. 29 Verstraeten R, Cossa M, Martinez L, et al. Epidemiology: the current burden of tuberculosis and its determinants. In: García-Basteiro AL, Öner Eyüboğlu F, Rangaka MX, eds. The Challenge of Tuberculosis in the 21st Century (ERS Monograph). Sheffield, European Respiratory Society, 2023 pp. 18–33. 30 Frascella B, Richards AS, Sossen B, et al. Subclinical tuberculosis disease -a review and analysis of prevalence surveys to inform definitions, burden, associations, and screening methodology. Clin Infect Dis 2021 73: e830–e841. Disclosures: M.X. Rangaka holds a Wellcome Investigator Award for a project that is unrelated to this Monograph. The remaining authors have nothing to disclose. https://doi.org/10.1183/2312508X.10025822 xvii